Concepts (133)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myocardial Infarction | 8 | 2021 | 1146 | 0.780 |
Why?
|
| Antihypertensive Agents | 5 | 2014 | 431 | 0.650 |
Why?
|
| Pancreatitis | 1 | 2021 | 294 | 0.640 |
Why?
|
| Blood Pressure | 3 | 2015 | 1559 | 0.630 |
Why?
|
| Hypertension | 8 | 2014 | 1583 | 0.550 |
Why?
|
| Prehypertension | 1 | 2015 | 13 | 0.490 |
Why?
|
| Coronary Disease | 3 | 2015 | 736 | 0.450 |
Why?
|
| Calcium Channel Blockers | 5 | 2013 | 143 | 0.410 |
Why?
|
| Drug Discovery | 1 | 2014 | 329 | 0.380 |
Why?
|
| Chlorthalidone | 5 | 2014 | 24 | 0.250 |
Why?
|
| Cerebrovascular Disorders | 1 | 2006 | 153 | 0.250 |
Why?
|
| Thrombolytic Therapy | 3 | 1995 | 248 | 0.240 |
Why?
|
| Stroke | 3 | 2014 | 1057 | 0.230 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2006 | 325 | 0.220 |
Why?
|
| Lisinopril | 4 | 2014 | 29 | 0.200 |
Why?
|
| Amlodipine | 4 | 2014 | 24 | 0.200 |
Why?
|
| Electrocardiography | 3 | 2021 | 1145 | 0.160 |
Why?
|
| Adrenergic beta-Antagonists | 3 | 2009 | 316 | 0.150 |
Why?
|
| Acute Disease | 1 | 2021 | 2489 | 0.140 |
Why?
|
| Cardiovascular Diseases | 4 | 2006 | 2209 | 0.130 |
Why?
|
| Drug Therapy, Combination | 2 | 2014 | 2325 | 0.120 |
Why?
|
| Heart Rate | 1 | 1997 | 738 | 0.110 |
Why?
|
| Hypolipidemic Agents | 1 | 2013 | 187 | 0.100 |
Why?
|
| Sex Factors | 2 | 2014 | 2170 | 0.090 |
Why?
|
| Peripheral Arterial Disease | 1 | 2014 | 265 | 0.090 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 3 | 2009 | 242 | 0.090 |
Why?
|
| Adrenergic alpha-1 Receptor Antagonists | 1 | 2009 | 24 | 0.080 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 2009 | 72 | 0.080 |
Why?
|
| Diuretics | 2 | 2013 | 172 | 0.080 |
Why?
|
| Digoxin | 1 | 2008 | 53 | 0.080 |
Why?
|
| Prostatic Hyperplasia | 1 | 2009 | 201 | 0.080 |
Why?
|
| Heart Failure, Systolic | 1 | 2008 | 34 | 0.080 |
Why?
|
| Cardiotonic Agents | 1 | 2008 | 156 | 0.070 |
Why?
|
| Dipyridamole | 1 | 2006 | 41 | 0.070 |
Why?
|
| Ticlopidine | 1 | 2006 | 49 | 0.070 |
Why?
|
| Cholesterol, Dietary | 1 | 1986 | 52 | 0.070 |
Why?
|
| Humans | 20 | 2021 | 270033 | 0.070 |
Why?
|
| Herpes Zoster | 1 | 2006 | 53 | 0.070 |
Why?
|
| Oxadiazoles | 1 | 1986 | 60 | 0.060 |
Why?
|
| Doxazosin | 1 | 2004 | 32 | 0.060 |
Why?
|
| Tissue Plasminogen Activator | 2 | 1995 | 162 | 0.060 |
Why?
|
| Molecular Targeted Therapy | 1 | 2014 | 2391 | 0.060 |
Why?
|
| Double-Blind Method | 4 | 2014 | 2586 | 0.060 |
Why?
|
| Aspirin | 1 | 2006 | 372 | 0.060 |
Why?
|
| Treatment Outcome | 6 | 2014 | 33691 | 0.050 |
Why?
|
| Male | 12 | 2021 | 127917 | 0.050 |
Why?
|
| Confidence Intervals | 2 | 2014 | 748 | 0.040 |
Why?
|
| Heart Failure | 2 | 2013 | 2319 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2014 | 6254 | 0.040 |
Why?
|
| Angina, Unstable | 2 | 1999 | 54 | 0.040 |
Why?
|
| Mibefradil | 1 | 1997 | 3 | 0.040 |
Why?
|
| Tetrahydronaphthalenes | 1 | 1997 | 114 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2014 | 12087 | 0.030 |
Why?
|
| Arteriosclerosis | 2 | 1987 | 175 | 0.030 |
Why?
|
| Endothelium | 2 | 1987 | 155 | 0.030 |
Why?
|
| Selection Bias | 1 | 1995 | 47 | 0.030 |
Why?
|
| Plasminogen Activators | 1 | 1995 | 55 | 0.030 |
Why?
|
| Anistreplase | 1 | 1995 | 1 | 0.030 |
Why?
|
| Streptokinase | 1 | 1995 | 24 | 0.030 |
Why?
|
| Diabetes Mellitus | 1 | 2004 | 1041 | 0.030 |
Why?
|
| Myocardial Stunning | 1 | 1994 | 17 | 0.030 |
Why?
|
| Rest | 1 | 1994 | 69 | 0.030 |
Why?
|
| Aged | 8 | 2014 | 73127 | 0.030 |
Why?
|
| Ventricular Function, Left | 2 | 1995 | 555 | 0.030 |
Why?
|
| Benzimidazoles | 1 | 1997 | 437 | 0.030 |
Why?
|
| Proportional Hazards Models | 2 | 2014 | 5099 | 0.030 |
Why?
|
| Shock, Cardiogenic | 1 | 1995 | 193 | 0.030 |
Why?
|
| Chest Pain | 1 | 1994 | 172 | 0.030 |
Why?
|
| Fibrinolytic Agents | 1 | 1995 | 293 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2005 | 2646 | 0.030 |
Why?
|
| Aorta | 2 | 1987 | 665 | 0.030 |
Why?
|
| Animals | 3 | 2014 | 61714 | 0.020 |
Why?
|
| Cause of Death | 1 | 2014 | 778 | 0.020 |
Why?
|
| Risk Factors | 3 | 2013 | 17824 | 0.020 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 1995 | 345 | 0.020 |
Why?
|
| Middle Aged | 8 | 2014 | 90030 | 0.020 |
Why?
|
| Receptors, Adrenergic, alpha-1 | 1 | 2009 | 38 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2014 | 15172 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2014 | 3523 | 0.020 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2009 | 142 | 0.020 |
Why?
|
| Rabbits | 2 | 1987 | 1012 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2013 | 2056 | 0.020 |
Why?
|
| Female | 8 | 2014 | 148486 | 0.020 |
Why?
|
| Cyclic GMP | 1 | 1987 | 113 | 0.020 |
Why?
|
| Isradipine | 1 | 1986 | 7 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2014 | 5061 | 0.020 |
Why?
|
| Parasympathetic Nervous System | 1 | 1986 | 26 | 0.020 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 1986 | 240 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 1995 | 6204 | 0.020 |
Why?
|
| Vasodilator Agents | 1 | 1987 | 229 | 0.020 |
Why?
|
| Age Factors | 1 | 2014 | 5449 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2014 | 4360 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2009 | 1185 | 0.010 |
Why?
|
| Incidence | 1 | 2013 | 5806 | 0.010 |
Why?
|
| Coronary Vessels | 1 | 1987 | 600 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2014 | 6752 | 0.010 |
Why?
|
| Diabetes Complications | 1 | 2004 | 302 | 0.010 |
Why?
|
| Coronary Angiography | 2 | 1995 | 533 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2009 | 4318 | 0.010 |
Why?
|
| Hemodynamics | 1 | 1986 | 935 | 0.010 |
Why?
|
| Hyperglycemia | 1 | 2004 | 337 | 0.010 |
Why?
|
| Survival Rate | 1 | 2014 | 12508 | 0.010 |
Why?
|
| Myoglobin | 1 | 1999 | 117 | 0.010 |
Why?
|
| Creatine Kinase | 1 | 1999 | 94 | 0.010 |
Why?
|
| Time Factors | 3 | 1999 | 12953 | 0.010 |
Why?
|
| Troponin I | 1 | 1999 | 130 | 0.010 |
Why?
|
| Troponin T | 1 | 1999 | 256 | 0.010 |
Why?
|
| United States | 1 | 2014 | 15776 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2006 | 4819 | 0.010 |
Why?
|
| Isoenzymes | 1 | 1999 | 650 | 0.010 |
Why?
|
| Vascular Patency | 1 | 1995 | 189 | 0.010 |
Why?
|
| Coronary Circulation | 1 | 1995 | 235 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 1995 | 591 | 0.010 |
Why?
|
| Single-Blind Method | 1 | 1995 | 415 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2013 | 30923 | 0.010 |
Why?
|
| Random Allocation | 1 | 1994 | 740 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 1995 | 1434 | 0.010 |
Why?
|
| Observer Variation | 1 | 1994 | 703 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2004 | 9464 | 0.010 |
Why?
|
| Linear Models | 1 | 1994 | 1095 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 1999 | 5153 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1995 | 3023 | 0.010 |
Why?
|
| Echocardiography | 1 | 1994 | 1223 | 0.000 |
Why?
|
| Biomarkers | 1 | 1999 | 5046 | 0.000 |
Why?
|
| Calcimycin | 1 | 1987 | 48 | 0.000 |
Why?
|
| Substance P | 1 | 1987 | 74 | 0.000 |
Why?
|
| Receptors, Muscarinic | 1 | 1987 | 71 | 0.000 |
Why?
|
| Nitroglycerin | 1 | 1987 | 45 | 0.000 |
Why?
|
| Histamine | 1 | 1987 | 60 | 0.000 |
Why?
|
| Acetylcholine | 1 | 1987 | 105 | 0.000 |
Why?
|
| Vasodilation | 1 | 1987 | 216 | 0.000 |
Why?
|
| Prospective Studies | 1 | 1999 | 13378 | 0.000 |
Why?
|
| Nitric Oxide | 1 | 1987 | 659 | 0.000 |
Why?
|